Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Caplin Point Laboratories Ltd
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 389 | 395 | 410 | 436 | 453 | 459 | 483 | 493 | 502 | 510 | 534 | 543 | 600 |
| Expenses + | 265 | 269 | 273 | 293 | 308 | 307 | 318 | 331 | 334 | 332 | 345 | 353 | 396 |
| Operating Profit | 124 | 127 | 137 | 142 | 145 | 152 | 165 | 162 | 168 | 178 | 189 | 190 | 204 |
| OPM % | 32% | 32% | 34% | 33% | 32% | 33% | 34% | 33% | 33% | 35% | 35% | 35% | 34% |
| Other Income + | 11 | 12 | 21 | 17 | 17 | 19 | 21 | 31 | 26 | 23 | 30 | 34 | 28 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 11 | 11 | 12 | 14 | 16 | 16 | 17 | 16 | 17 | 16 | 18 | 19 | 19 |
| Profit before tax | 124 | 127 | 146 | 145 | 146 | 154 | 168 | 177 | 177 | 184 | 201 | 204 | 213 |
| Tax % | 18% | 18% | 20% | 18% | 17% | 19% | 22% | 21% | 18% | 18% | 20% | 19% | 19% |
| Net Profit + | 101 | 104 | 116 | 120 | 121 | 125 | 131 | 140 | 145 | 151 | 160 | 166 | 173 |
| EPS in Rs | 13.45 | 13.62 | 15.13 | 15.43 | 16.01 | 16.31 | 17.21 | 18.28 | 18.76 | 20.10 | 20.32 | 21.56 | 22.38 |
Financials of Caplin Point Laboratories Ltd
Annual income statement trend
| Jun 2015 | Mar 2016 9m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 252 | 239 | 402 | 540 | 649 | 863 | 1,061 | 1,269 | 1,467 | 1,694 | 1,937 | 2,187 |
| Expenses + | 192 | 175 | 276 | 345 | 417 | 603 | 732 | 874 | 1,025 | 1,142 | 1,287 | 1,426 |
| Operating Profit | 60 | 64 | 125 | 195 | 232 | 260 | 329 | 395 | 442 | 552 | 651 | 761 |
| OPM % | 24% | 27% | 31% | 36% | 36% | 30% | 31% | 31% | 30% | 33% | 34% | 35% |
| Other Income + | 3 | 4 | 10 | 13 | 19 | 41 | 23 | 38 | 55 | 66 | 92 | 116 |
| Interest | 1 | 0 | 1 | 1 | 1 | 0 | 2 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 8 | 7 | 13 | 19 | 23 | 32 | 37 | 47 | 45 | 53 | 66 | 73 |
| Profit before tax | 53 | 60 | 121 | 188 | 227 | 269 | 314 | 386 | 451 | 564 | 677 | 803 |
| Tax % | 23% | 24% | 21% | 23% | 22% | 20% | 20% | 20% | 16% | 18% | 20% | 19% |
| Net Profit + | 41 | 46 | 96 | 145 | 177 | 215 | 251 | 308 | 377 | 461 | 541 | 650 |
| EPS in Rs | 5.43 | 6.05 | 12.65 | 19.15 | 23.35 | 28.42 | 32.03 | 39.56 | 49.57 | 60.19 | 70.56 | 84.36 |
| Dividend Payout % | 18% | 20% | 12% | 10% | 9% | 9% | 9% | 10% | 9% | 8% | 8% | 5% |
Financials of Caplin Point Laboratories Ltd
Capital structure and asset base
| Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
| Reserves | 78 | 113 | 210 | 349 | 582 | 858 | 954 | 1,252 | 1,649 | 2,084 | 2,619 | 3,571 |
| Borrowings + | 2 | 2 | 1 | 1 | 36 | 113 | 235 | 219 | 222 | 219 | 222 | 5 |
| Other Liabilities + | 134 | 137 | 133 | 136 | 109 | 139 | 159 | 250 | 305 | 380 | 352 | 454 |
| Total Liabilities | 229 | 267 | 358 | 500 | 743 | 1,126 | 1,364 | 1,736 | 2,191 | 2,698 | 3,208 | 4,045 |
| Fixed Assets + | 113 | 144 | 152 | 169 | 227 | 272 | 305 | 287 | 280 | 453 | 546 | 605 |
| CWIP | 31 | 0 | 3 | 15 | 10 | 20 | 14 | 18 | 221 | 117 | 144 | 209 |
| Investments | 0 | 0 | 17 | 47 | 70 | 61 | 11 | 89 | 281 | 376 | 590 | 859 |
| Other Assets + | 85 | 122 | 186 | 269 | 436 | 772 | 1,033 | 1,343 | 1,410 | 1,753 | 1,928 | 2,373 |
| Total Assets | 229 | 267 | 358 | 500 | 743 | 1,126 | 1,364 | 1,736 | 2,191 | 2,698 | 3,208 | 4,045 |
Financials of Caplin Point Laboratories Ltd
Operating, investing and financing cash movement
| Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 50 | 42 | 68 | 66 | 83 | 45 | 269 | 337 | 271 | 318 | 432 | 523 |
| Cash from Investing Activity + | -23 | -6 | -36 | -69 | -100 | -54 | -30 | -377 | -216 | -319 | -333 | -582 |
| Cash from Financing Activity + | -9 | -14 | -7 | -12 | 90 | 80 | -24 | -41 | -28 | -38 | -38 | -46 |
| Net Cash Flow | 19 | 23 | 25 | -14 | 73 | 70 | 215 | -81 | 27 | -39 | 61 | -106 |
| Free Cash Flow | 24 | 34 | 43 | 18 | 18 | -32 | 195 | 246 | 78 | 173 | 241 | 275 |
| CFO/OP | 103% | 92% | 73% | 53% | 54% | 38% | 102% | 106% | 81% | 77% | 86% | 88% |
Financials of Caplin Point Laboratories Ltd
Working capital efficiency and return ratios
| Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 8 | 12 | 30 | 85 | 90 | 97 | 96 | 91 | 98 | 117 | 119 | 138 |
| Inventory Days | 37 | 57 | 44 | 44 | 47 | 210 | 139 | 149 | 159 | 183 | 159 | 181 |
| Days Payable | 112 | 168 | 155 | 144 | 76 | 57 | 68 | 102 | 84 | 116 | 103 | 125 |
| Cash Conversion Cycle | -67 | -99 | -81 | -16 | 61 | 251 | 166 | 138 | 173 | 184 | 175 | 194 |
| Working Capital Days | -128 | -114 | -29 | 47 | 104 | 167 | 145 | 165 | 144 | 166 | 174 | 263 |
| ROCE % | 68% | 62% | 68% | 63% | 45% | 33% | 28% | 28% | 26% | 26% | 26% | 25% |